Reverse Transcriptase Multi-Class Drug Resistance and Rilpivirine Susceptibility in Diverse HIV-1 Subtypes
不同 HIV-1 亚型中的逆转录酶多类耐药性和利匹韦林敏感性
基本信息
- 批准号:9353524
- 负责人:
- 金额:$ 12.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-07-01 至 2020-05-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAddressAffectAffinityAnti-HIV AgentsBiochemicalClinical DataClinical ResearchComplexDevelopmentDrug DesignDrug resistanceEthiopiaGenerationsGoalsHIVHIV-1HIV-1 drug resistanceHealthHighly Active Antiretroviral TherapyInfectionMolecularMutationNevirapinePatientsPatternPharmaceutical PreparationsPhenotypePredispositionPrevalenceRNA-Directed DNA PolymeraseResistanceReverse Transcriptase InhibitorsReverse TranscriptionRibonuclease HSamplingStructureTestingTimeVertebral columnVirusbaseclinical sequencingclinically relevantcohortefavirenzeffective therapyexperiencefitnessinsightlow and middle-income countriesmultidrug resistance inhibition therapynon-nucleoside reverse transcriptase inhibitorsnovel therapeuticspressureresistance mechanismresistance mutationtreatment strategy
项目摘要
DESCRIPTION (provided by applicant): Reverse transcriptase (RT) inhibitors comprise two different classes, nucleos(t)ide RT inhibitors (NRTIs) and nonnucleoside RTIs (NNRTIs), which act by entirely different mechanisms. However, their extensive use has led to the emergence of drug resistance mutations that may affect use of new RTIs. As new drugs like rilpivirine (RPV) become increasingly available to patients infected with HIV strains of subtypes other than B (HIV-nonB), it is important to understand how RPV resistance-associated mutations determined in HIV-1B samples (RAMB) affect susceptibility patterns in both drug-naïve or -treated HIV-nonB patients. This proposal aims to understand differences in drug resistance among different HIV subtypes (HIV-1B vs. HIV-nonB). Recent collaborative clinical data (with A. Sönnerborg and U. Neogi) identified RAMBs in treatment-naïve (6- 11%, depending on subtype) and nevirapine (NVP) or efavirenz (EFV)-based therapy-failed patients (22-34%, depending on subtype). Hence, it is hypothesized that patients who failed NVP/EFV-based therapy are more likely to fail RPV-based therapy. Moreover, patients treated with TDF/FTC/RPV failed therapy through RPV- associated mutations in ~9% of HIV-1B patients compared to ~25% of HIV-nonB patients. Preliminary analysis of RT sequences from clinical cohorts of HIV-1B and HIV-nonB patients that are treatment-naïve or -failed (NVP/EFV-based) showed an increase in prevalence of predicted RAMBs. Hence, it is also hypothesized that RPV resistance emerges through different mechanisms in various subtypes. Furthermore, until recently, it was thought resistance to one class of RTIs was unrelated to the other. However, RT connection subdomain mutations (CSMs), namely N348I in HIV-1B, have been identified, which give multi-class drug resistance (MCDR) to both NRTIs and NNRTIs. It is hypothesized that CSMs affect MCDR differently in various HIV subtypes. The following aims will be addressed: SA 1. Determine how the presence of CSMs and RAMBs affect RPV susceptibility of HIV-1B and -nonB SA 2. Virologically characterize the contribution of CSMs and RAMBs on fitness and multi-class resistance in multiple subtypes SA 3. Unravel biochemical and structural mechanisms of the MCDR phenotype in HIV-1B and HIV-nonB The goal of this application is to elucidate the molecular mechanisms underlying MCDR and how CSMs may impact the RPV susceptibility of different HIV subtypes, providing important insights into the feasibility of RPV as first-line therapy in HIV
1B and HIV-nonB patients.
描述(由申请人提供):逆转录酶(RT)抑制剂包括两种不同的类别,核苷(酸)RT抑制剂(NRTI)和非核苷RT抑制剂(NNRTI),它们通过完全不同的机制发挥作用。然而,它们的广泛使用导致了可能影响新RTI使用的耐药突变的出现。随着利匹韦林(RPV)等新药越来越多地用于感染非B亚型HIV毒株(HIV-非B)的患者,了解HIV-1 B样本(RAMB)中确定的RPV耐药相关突变如何影响未经药物治疗或接受过药物治疗的HIV-非B患者的敏感性模式非常重要。该提案旨在了解不同HIV亚型(HIV-1B与HIV-nonB)之间的耐药性差异。最近的合作临床数据(与A。Sönnerborg和U. Neogi)在初治患者(6- 11%,取决于亚型)和奈韦拉平(NVP)或依法韦仑(EFV)治疗失败的患者(22- 34%,取决于亚型)中发现了RAMB。因此,假设基于NVP/EFV的治疗失败的患者更有可能基于RPV的治疗失败。此外,接受TDF/FTC/RPV治疗的患者中,约9%的HIV-1B患者因RPV相关突变而治疗失败,而HIV-非B患者约为25%。对来自HIV-1B和HIV-非B患者临床队列的RT序列进行初步分析,这些患者均为未经治疗或治疗失败(基于NVP/EFV),结果显示预测的RAMB患病率增加。因此,还假设RPV抗性在不同亚型中通过不同机制出现。此外,直到最近,人们还认为对一类RTI的耐药性与另一类RTI无关。然而,HIV-1B中的RT连接亚结构域突变(CSM),即N348 I,已被鉴定,其对NRTI和NNRTI产生多类耐药(MCDR)。假设CSM在不同的HIV亚型中对MCDR的影响不同。将讨论以下目标:SA 1。确定CSM和RAMB的存在如何影响RPV对HIV-1B和-nonB SA 2的易感性。从病毒学上表征CSM和RAMB对多种亚型SA 3中适应性和多类耐药的贡献。揭示HIV-1B和HIV-nonB中MCDR表型的生化和结构机制本申请的目的是阐明MCDR的分子机制以及CSM如何影响不同HIV亚型的RPV易感性,为RPV作为HIV一线治疗的可行性提供重要见解。
1B和HIV-非B患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stefan G Sarafianos其他文献
Biochemical mechanism of clinical resistance to rilpivirine
- DOI:
10.1186/1471-2334-12-s1-p94 - 发表时间:
2012-05-04 - 期刊:
- 影响因子:3.000
- 作者:
Kamalendra Singh;Devendra K Rai;Bechan Sharma;Eleftherios Michailidis;Emily M Ryan;Kayla B Matzek;Maxwell D Leslie;Ariel N Hagedorn;Hong-Tao Xu;Mark A Wainberg;Bruno Marchand;Stefan G Sarafianos - 通讯作者:
Stefan G Sarafianos
The Combination of 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine with Rilpivirine Shows Synergistic Anti-HIV-1 Activ- ity In Vitro
4-乙炔基-2-氟-2-脱氧腺苷与利匹韦林的组合在体外显示出协同抗 HIV-1 活性
- DOI:
- 发表时间:
2012 - 期刊:
- 影响因子:0
- 作者:
Atsuko Hachiya;Bruno Marchand;Eleftherios Michailidis;Eiichi N Kodama;Michael A Parni- ak;Hiroaki Mitsuya;Shinichi Oka;Stefan G Sarafianos - 通讯作者:
Stefan G Sarafianos
Stefan G Sarafianos的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stefan G Sarafianos', 18)}}的其他基金
Discovery of SARS-CoV-2 antivirals using a replicon assay
使用复制子测定发现 SARS-CoV-2 抗病毒药物
- 批准号:
10522048 - 财政年份:2022
- 资助金额:
$ 12.41万 - 项目类别:
Discovery of SARS-CoV-2 antivirals using a replicon assay
使用复制子测定发现 SARS-CoV-2 抗病毒药物
- 批准号:
10673119 - 财政年份:2022
- 资助金额:
$ 12.41万 - 项目类别:
Behavior of HIV in Viral Environments (B-HIVE)
HIV 在病毒环境中的行为 (B-HIVE)
- 批准号:
10650864 - 财政年份:2022
- 资助金额:
$ 12.41万 - 项目类别:
Behavior of HIV in Viral Environments (B-HIVE)
HIV 在病毒环境中的行为 (B-HIVE)
- 批准号:
10508443 - 财政年份:2022
- 资助金额:
$ 12.41万 - 项目类别:
Taking aim at HBV eradication using novel NRTIs and Capsid effectors
使用新型 NRTI 和衣壳效应物消灭 HBV
- 批准号:
9918244 - 财政年份:2017
- 资助金额:
$ 12.41万 - 项目类别:
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV
野生型和多重耐药艾滋病毒的超强抑制剂
- 批准号:
9605989 - 财政年份:2017
- 资助金额:
$ 12.41万 - 项目类别:
Taking aim at HBV eradication using novel NRTIs and Capsid effectors
使用新型 NRTI 和衣壳效应物消灭 HBV
- 批准号:
9605893 - 财政年份:2017
- 资助金额:
$ 12.41万 - 项目类别:
Reverse Transcriptase Multi-Class Drug Resistance and Rilpivirine Susceptibility in Diverse HIV-1 Subtypes
不同 HIV-1 亚型中的逆转录酶多类耐药性和利匹韦林敏感性
- 批准号:
9140626 - 财政年份:2016
- 资助金额:
$ 12.41万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 12.41万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 12.41万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 12.41万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 12.41万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 12.41万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 12.41万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 12.41万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 12.41万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 12.41万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 12.41万 - 项目类别:
Research Grant